Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Navin Fluorine International - FY22 could see steady growth - ICICI Securities

Posted On: 2021-01-27 22:45:11 (Time Zone: Arizona, USA)


Navin Fluorine International's (NFIL) Q3FY21 EBITDA grew 26% YoY on strong growth in CRAMS revenue (up 51% YoY), steady print in specialty (up 26% YoY) and lower costs. However, we are a tad disappointed on gross margin dip despite rising mix of CRAMS and specialty. CRAMS had a strong print driven by commercialisation of two products, and there is visibility for two more. This increases our confidence in the business. We note that rising contribution from commercialised products helps improve customer engagement, maintain plant utilisation and reduce volatility. FY22 revenue growth guidance is steady, and capacity constraints don't seem to hurt NFIL. We maintain our estimates and increase our target price for the stock to Rs2,338 (from Rs2,086) on valuation rollover to FY23E. Maintain REDUCE.

- CRAMS drives revenue growth. Standalone revenues rose 17.9% YoY to Rs3bn driven by CRAMS revenue rise of 51% to Rs0.7bn, and specialty chemicals revenue growth of 25.8% to Rs1.2bn. Ref-gas revenues were down 17.5% YoY to Rs470mn while inorganic fluoride revenues grew 11.8% YoY to Rs570mn. CRAMS business was aided by supply for one commercialised product, and another product close to commercialisation. Company is seeing traction in two other molecules with commercialisation potential.

- Gross margin shrunk despite higher revenues from CRAMS/specialty. Gross margin dipped 100bps YoY / 325bps QoQ to 54.2%. EBITDA rose by a strong 26% YoY to Rs823mn on continued cost benefit and operating leverage while EBITDA margin came in at 27.8% (up 185bps YoY). Employee costs rose only 0.2% YoY and other expenses dipped 2%, which benefited EBITDA. Net profit grew 29.6% YoY to Rs587mn.

- Steady revenue growth outlook for FY22. NFIL has guided for a steady FY22 with low teens growth in ref-gas and inorganic fluoride driven by volumes. Ref-gas should benefit from higher sale for non-emissive use and likely better realisations, and inorganic fluoride from addition of new customers. Specialty segment should continue to grow at 20% p.a. despite capacity constraints on debottlenecking. Company aims to reduce volatility in CRAMS and is targeting steady revenues of at least US$10mn each quarter.

- Other highlights. 1) NFIL targets to achieve >2x asset turn on Rs2.15bn investment in CRAMS by FY23; 2) two new customers have been added in the inorganic segment, one each in India and the US, who provide good visibility for growth; NFIL saw early teens growth even in Q4FY21; 3) R-22 non-emissive sales comprised 20% of volumes and it is expected to ramp up over the next few years as emissive volumes are cut; 4) present molecule portfolio is 20-25, and it has qualified molecule of 15 in the pipeline, which should get commercialised in the next two years; 5) NFIL sees >20% revenue growth for specialty segment in Q4FY21; 6) in CRAMS, NFIL competes for small molecules used as intermediates for pharma products. The initial demand for these molecules is <100tpa, and don't see immediate need for dedicated facilities. However, NFILis in talks with innovators on understanding the demand cycle for the products that are commercialised.

Shares of Navin Fluorine International Limited was last trading in BSE at Rs.2480.3 as compared to the previous close of Rs. 2568.4. The total number of shares traded during the day was 11493 in over 2233 trades.

The stock hit an intraday high of Rs. 2589.95 and intraday low of 2460.55. The net turnover during the day was Rs. 28896927.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

4th Industrial Conclave - Bullish undertone, favourable valuation - HDFC Securities

Sanofi India - Weak quarter; sequential improvement - ICICI Securities

Sunteck Realty - All eyes on upcoming launches - ICICI Securities

Company Update - Tata Motors - ICICI Direct

Q4CY20 Company Update - Mahindra CIE Automotive - ICICI Direct

Event Update - Hindalco - ICICI Direct

EY report launch at BioAsia 2021 - Moving the needle: Healthcare industry in a post-COVID world

Initiating Coverage - Dalmia Bharat Ltd - HDFC Securities Retail Research Desk

Initiating Coverage - Mastek Ltd - HDFC Securities Retail Research Desk

Hindalco Industries - Status quo maintained - ICICI Securities

Tata Motors - India business scaling in the right direction - ICICI Securities

IPO Review - Heranba Industries Ltd

Company Update - Narayana Hrudayalaya - ICICI Direct

Ambuja Cements - Market share sustenance key for rerating - ICICI Securities

ADD on Astral Poly Technik - An 'astr'onomical growth story - HDFC Securities

FMCG Sector Update Report - Divergence narrows; refocus on core - HDFC Securities

Maintain REDUCE on Jubilant FoodWorks - More legs for growth; reflecting confidence on core - HDFC Securities

Torrent Power - Growth acceleration - ICICI Securities

Mahindra CIE Automotive - CY20 performance closes on a strong note - ICICI Securities

Q3FY21 Company Update - V-Guard Industries - ICICI Direct

Quant Pick - Indus Towers - ICICI Direct

Q4CY20 Result Update - Ambuja Cement - ICICI Direct

Q3FY21 Company Update - Nesco Ltd - ICICI Direct

Maintain BUY on Ambuja Cements - Healthy quarter; multiple triggers ahead - HDFC Securities

Heranba Industries Ltd. - IPO - Sound Financials & Promising Outlook Augur Well

India Equity Strategy Report - Quarterly flipbook: Q3 - upgrades galore! - HDFC Securities

Earnings Wrap Q3FY21: Encouraging quarter, broad based recovery under way!

Shilpa Medicare - USFDA import alert at Jadcherla unit - ICICI Securities

Q3FY21 Company Update - Indian Bank - ICICI Direct

Quant Pick - Torrent Power - ICICI Direct

GE T&D India - Strong cashflow - ICICI Securities

Q3FY21 Result Update - Graphite India - ICICI Direct

Q4CY2020 Result Update - Varun Beverages - ICICI Direct

Q3FY21 Company Update - NBCC Ltd - ICICI Direct

Quant Pick - United Breweries - ICICI Direct

Q4CY2020 Result Update - Nestlé India - ICICI Direct

Q3FY21 Result Update - Time Technoplast - ICICI Direct

Healthy Business Performance Puts ITC Stock Recovery on Track

Gold - Feb 17, 2021 - Reliance Securities

Maintain REDUCE on Nestle India - Steady revenue show; employee cost dents margins - HDFC Securities

Varun Beverages - Q4 CY20 Result and Concall Update - YES Securities

Nestle India - Q4 CY20 Result Update - YES Securities

Reiterate BUY on JMC Projects - Some hits, some misses - HDFC Securities

Varun Beverages - Strong volumes; higher margins - ICICI Securities

Computer Age Management Services - Play on industry AUM growth - ICICI Securities

Nestle India - Just a tad underwhelming (given the high benchmarks expected from Nestle India) - ICICI Securities

NHPC - Earnings robust; projects on track - ICICI Securities

Maintain BUY on ITD Cementation - Gradual recovery shaping up - HDFC Securities

Techno Electric & Engineering - Strong margins, healthy growth outlook - ICICI Securities

Time Technoplast - Outlook upbeat; execution remains key - ICICI Securities



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020